Dept. of Neurosurgery, Rigshospitalet, University of Copenhagen
Copenhagen, 2100, Denmark
NCT Number: NCT01825044
This is an open label study on the pharmacokinetics and safety of ciclosporin in patients with severe traumatic brain injury, who require intensive care unit admission and monitoring of intracranial pressure via a ventricular catheter. 20 patients will be screened, and subsequently enrolled after clinical stabilisation. Thereafter, patients will receive 2.5 mg/kg bolus dose infusion of ciclosporin, followed by either 5 mg/kg/day or 10 mg/kg/day of ciclosporin as continuous infusion for 5 days+3 days monitoring at the intensive care unit. After an additional 30 days, a follow-up phone call will be made to the patient, or the patient's nursing staff, checking patient status and serious adverse events. The two dose levels will be investigated in 10 patients each, starting with the lower dose level for the first 10 patients. Patients will have samples of blood and cerebrospinal fluid drawn at pre-defined time points during the study for pharmacokinetic assessment and evaluation of biomarkers. Bedside monitoring with microdialysis and brain tissue oxygenation will be performed. The safety monitoring includes nephrotoxicity, hepatotoxicity, monitoring of intracranial pressure (ICP), infections monitoring and adverse events collection and reporting.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Interventional
Phase 2
Copenhagen, 2100, Denmark
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
rosuvastatin, tacrolimus, Hypericum perforatum (St.John´s Wort; a herbal dietary supplement), stiripentol, aliskiren, bosentan, diltiazem, verapamil and antiepileptics.
Intravenous bolus of NeuroSTAT (Ciclosporin) 2.5 mg/kg bodyweight followed by 5 days of 5 mg/kg bodyweight/day continuous infusion
Other names: Ciclosporin 5 mg/kg/day
Intravenous bolus of NeuroSTAT (Ciclosporin) 2.5 mg/kg bodyweight followed by 5 days of 10 mg/kg bodyweight/day continuous infusion
Other names: Ciclosporin 10 mg/kg/day
Time frame: Prespecified timepoints during 8 days (PK)
Peak Plasma Concentration (Cmax) of Ciclosporin and Area under the blood concentration versus time curve (AUC) of Ciclosporin. This will characterise the pharmacokinetic profile of the two chosen dosing regimens of ciclosporin in severe Traumatic Brain Injury (TBI) patients.
Time frame: 38 days
Including:
Time frame: Prespecified timepoints during 8 days
The CSF samples will be drawn from the EVD-catheter at the same time points as in blood to document central nervous system penetration of ciclosporin
Time frame: Measured at prespecified timepoints during 8 days
Kidney Injury Molecule (KIM)-1, creatinine and Cystatin-C in urine samples
Time frame: During 8 days
The background pattern will be interpreted and analysed by an EEG program. The aim is to find evidence if EEG analyses could be used to predict clinical outcome.
Time frame: Measured at prespecified timepoints during 8 days
Microdialysis in the most and least traumatised side pre-treatment and every second hour until the end of day 8
Time frame: During 8 days
Continuously (every 5th second) measured directly using an indwelling probe.
NeuroVive Pharmaceutical AB
Industry
An Open-label, Uncontrolled Phase II-study to Investigate Pharmacokinetics, Safety and Biomarkers of Effectiveness of NeuroSTAT® (Ciclosporin) in Patients With Severe Traumatic Brain Injury (TBI)
Acronym: CHIC
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01287156
Brain Diseases, Brain Injuries
Washington D.C., District of Columbia, United States
View Trial DetailsNCT05714150
Brain Diseases, Brain Injuries
Gainesville, Florida, United States
View Trial DetailsNCT04056312
Brain Diseases, Brain Injuries
West Orange, New Jersey, United States
View Trial DetailsNCT01132937
Brain Diseases, Brain Injuries
Bethesda, Maryland, United States
View Trial Details